Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the reporting period of August 2026 for Radiopharm Theranostics Limited, a foreign private issuer headquartered in Carlton South, Victoria, Australia. The filing serves to report a material corporate announcement made to the Australian Securities Exchange (ASX) on August 20, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a clinical trial milestone rather than a financial statement.
Material Changes and Operational Updates
- Clinical Trial Progress: The Company announced that its 177Lu-RAD202 Phase 1 HEAT Trial has advanced to Cohort 4.
- Regulatory Status: The registrant files annual reports under Form 20-F.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future earnings, or a detailed risk factor analysis beyond the standard incorporation by reference into the Company's Form F-3 registration statement. The primary focus is the operational milestone of advancing the HEAT Trial.
Key Facts for Investor Verification
- Verify the specific inclusion criteria and patient enrollment status for Cohort 4 of the 177Lu-RAD202 Phase 1 HEAT Trial.
- Review the attached Exhibit 99.1 for the full text of the ASX announcement regarding the trial advancement.
- Confirm the Company's current cash runway and funding status in subsequent filings, as this 6-K does not disclose financial liquidity.